Lyophilized Injectable Market (Type of Packaging: Single-use Vials, Point-of-care Reconstitution, and Specialty Packaging; Type of Delivery: Prefilled Diluent Syringes, Proprietary Reconstitution Devices, Single-step Devices, and Multi-step Devices; Indication: Autoimmune Diseases, Infectious Diseases, Metabolic Conditions, and Others; and End User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, and Others) - Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2023-2032

The global lyophilized injectable market size was exhibited at USD 2.91 billion in 2022 and is projected to hit around USD 5.17 billion by 2032, growing at a CAGR of 5.9% during the forecast period 2023 to 2032.

lyophilized injectable market size

Key Pointers:

  • In terms of type of packaging, the global lyophilized injectable market has been classified into single-use vials, point-of-care reconstitution, and specialty packaging
  • Based on type of delivery, the global lyophilized injectable market has been categorized into prefilled diluent syringes, proprietary reconstitution devices, single-step devices, and multi-step devices
  • In terms of indication, the global lyophilized injectable market has been segregated into autoimmune diseases, metabolic conditions, infectious diseases, and others
  • Based on end user, the global lyophilized injectable market has been divided into hospitals, specialty clinics, ambulatory surgical centers, and others
  • Each of the segments has been analyzed in detail for trends, recent trends & developments, drivers, restraints, opportunities, and useful insights. The lyophilized injectable market report provides current and future revenue for each of these segments for the period from 2018 to 2032, considering 2022 as the base year.

Lyophilization is the most commonly used method for the manufacturing of parenteral pharmaceutical products, when the product is unstable in aqueous solution. It is central to the protection of materials, which require low moisture content (less than 1%) in order to ensure stability and require a sterile and gentle preservation process.

Improved quality and shelf life of lyophilized drugs has attracted industry experts to implement lyophilization in their manufacturing processes. Contract research and manufacturing organizations have increased the use of lyophilized injectable drugs to provide quality products to customers. Therefore, rapidly growing contract research manufacturing services (CRAMS) is projected to drive the global lyophilized injectable market.

Lyophilized injectable drugs are stable at ambient temperatures and only require simple rehydration to be ready to use. This removes many sources of pipetting errors, while streamlining and simplifying workflows.

Elimination of the cold chain minimizes costs and carbon footprint, and provides a positive environmental impact by minimizing the need of expanded polystyrene (EPS or ‘Styrofoam’) containers often utilized to ship temperature-controlled products

Lyophilized products are considered safe for use, while delivering the desired functionality compared to non-lyophilized products. Moreover, lyophilization helps retain the biological and chemical activity of the chemical compound in the final product. This drives the demand for lyophilized injectable drugs in the pharmaceutical and biotechnology industries.

The ever-evolving nature of coronavirus has become a major threat to the public health, owing to its severe respiratory symptoms. Ongoing studies are surfacing about the safety and efficacy of novel lyophilized therapeutic agents in hospitalized adult patients diagnosed with COVID-19. Amid all this, healthcare giant Cipla - a global pharmaceutical company is gaining recognition for introducing its CIPREMI, a remdesivir lyophilized powder for injection (100mg). Manufacturers in the lyophilized injectable market are taking cues from such innovations to increase the availability of the U.S. FDA-approved emergency use authorization (EUA) treatment for patients with severe COVID-19 symptoms.

Since India is suffering from a third wave of the pandemic, companies in the India lyophilized injectable market are increasing efforts to gain regulatory approval by the Drug Controller General of India (DCGI) for restricted emergency use in the country.

Lyophilized injectable Market Segmentation

By Type of Packaging By Type of Delivery By Indication By End User

Single-use Vials

Point-of-care Reconstitution

Specialty Packaging

Prefilled Diluent Syringes

Proprietary Reconstitution Devices

Single-step Devices

Multi-step Devices

Autoimmune Diseases

Infectious Diseases

Metabolic Conditions

Others

Hospitals

Ambulatory Surgical Centers

Specialty Clinics

Others

Lyophilized injectable Market Key Players And Regions

Companies Profiled Regions Covered

B. Braun Melsungen AG

Baxter International, Inc.

BD

Schott AG

Aristopharma Ltd.

Vetter Pharma

Jubilant HollisterStier LLC

among others

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

 

Frequently Asked Questions

The global lyophilized injectable market size was exhibited at USD 2.91 billion in 2022 and is projected to hit around USD 5.17 billion by 2032

The global lyophilized injectable market is growing at a compound annual growth rate (CAGR) of 5.9% from 2023 to 2032.

Lyophilized injectable market is driven by rapidly growing contract research manufacturing services (CRAMS) and expansion of pipeline of lyophilized injectable drugs

The end-use segments in lyophilized injectable market are hospitals, ambulatory surgical centers and specialty clinics

Chapter 1. Introduction

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Lyophilized Injectable Market 

4. Market Overview

    4.1. Introduction & Overview

    4.2. Market Dynamics

        4.2.1. Drivers

        4.2.2. Restraints

        4.2.3. Opportunities 

    4.3. Global Lyophilized Injectable Market Analysis and Forecast, 2018–2032

5. Market Outlook 

    5.1. COVID-19 Pandemics Impact on Industry

    5.2. Key Industry Developments

    5.3. Pipeline Analysis

    5.4. Top 10 Lyophilized Drug Products

    5.5. Regulatory Scenario

6. Global Lyophilized Injectable Market Analysis and Forecast, by Type of Packaging

    6.1. Introduction & Definition

    6.2. Global Lyophilized Injectable Market Value  Forecast, by Type of Packaging, 2018–2032

        6.2.1. Single-use Vials

        6.2.2. Point-of-care Reconstitution

        6.2.3. Specialty Packaging

    6.3. Global Lyophilized Injectable Market Attractiveness Analysis, by Type of Packaging

7. Global Lyophilized Injectable Market Analysis and Forecast, by Type of Delivery

    7.1. Introduction & Definition

    7.2. Global Lyophilized Injectable Market Value  Forecast, by Type of Delivery, 2018–2032

        7.2.1. Prefilled Diluent Syringes

        7.2.2. Proprietary Reconstitution Devices

        7.2.3. Single-step Devices

        7.2.4. Multi-step Devices

    7.3. Global Lyophilized Injectable Market Attractiveness Analysis, by Type of Delivery

8. Global Lyophilized Injectable Market Analysis and Forecast, by Indication

    8.1. Introduction & Definition

    8.2. Global Lyophilized Injectable Market Value  Forecast, by Indication, 2018–2032

        8.2.1. Autoimmune Diseases

        8.2.2. Metabolic Conditions

        8.2.3. Infectious Diseases

        8.2.4. Others

    8.3. Global Lyophilized Injectable Market Attractiveness Analysis, by Indication

9. Global Lyophilized Injectable Market Analysis and Forecast, by End-user

    9.1. Introduction & Definition

    9.2. Global Lyophilized Injectable Market Value  Forecast, by End-user, 2018–2032

        9.2.1. Hospitals

        9.2.2. Ambulatory Surgical Centers

        9.2.3. Specialty Clinics

        9.2.4. Others

    9.3. Global Lyophilized Injectable Market Attractiveness Analysis, by End-user

10. Global Lyophilized Injectable Market Analysis and Forecast, by Region

    10.1. Key Findings

    10.2. Global Lyophilized Injectable Market Value  Forecast, by Region

        10.2.1. North America

        10.2.2. Europe

        10.2.3. Asia Pacific

        10.2.4. Latin America

        10.2.5. Middle East & Africa

    10.3. Global Lyophilized Injectable Market Attractiveness Analysis, by Region

11. North America Lyophilized Injectable Market Analysis and Forecast

    11.1. Introduction

    11.2. North America Lyophilized Injectable Market Value  Forecast, by Type of Packaging, 2018–2032

        11.2.1. Single-use Vials

        11.2.2. Point-of-care Reconstitution

        11.2.3. Specialty Packaging

    11.3. North America Lyophilized Injectable Market Value  Forecast, by Type of Delivery, 2018–2032

        11.3.1. Prefilled Diluent Syringes

        11.3.2. Proprietary Reconstitution Devices

        11.3.3. Single-step Devices

        11.3.4. Multi-step Devices

    11.4. North America Lyophilized Injectable Market Value  Forecast, by Indication, 2018–2032

        11.4.1. Autoimmune Diseases

        11.4.2. Metabolic Conditions

        11.4.3. Infectious Diseases

        11.4.4. Others 

    11.5. North America Lyophilized Injectable Market Value  Forecast, by End-user, 2018–2032

        11.5.1. Hospitals

        11.5.2. Ambulatory Surgical Centers

        11.5.3. Specialty Clinics

        11.5.4. Others

    11.6. North America Lyophilized Injectable Market Value  Forecast, by Country, 2018–2032

        11.6.1. U.S.

        11.6.2. Canada

    11.7. North America Lyophilized Injectable Market Attractiveness Analysis

        11.7.1. By Type of Packaging

        11.7.2. By Type of Delivery

        11.7.3. By Indication

        11.7.4. By End-user

        11.7.5. By Country 

12. Europe Lyophilized Injectable Market Analysis and Forecast

    12.1. Introduction

    12.2. Europe Lyophilized Injectable Market Value  Forecast, by Type of Packaging, 2018–2032

        12.2.1. Single-use Vials

        12.2.2. Point-of-care Reconstitution

        12.2.3. Specialty Packaging

    12.3. Europe Lyophilized Injectable Market Value  Forecast, by Type of Delivery, 2018–2032

        12.3.1. Prefilled Diluent Syringes

        12.3.2. Proprietary Reconstitution Devices

        12.3.3. Single-step Devices

        12.3.4. Multi-step Devices

    12.4. Europe Lyophilized Injectable Market Value  Forecast, by Indication, 2018–2032

        12.4.1. Autoimmune Diseases

        12.4.2. Metabolic Conditions

        12.4.3. Infectious Diseases

        12.4.4. Others 

    12.5. Europe Lyophilized Injectable Market Value  Forecast, by End-user, 2018–2032

        12.5.1. Hospitals

        12.5.2. Ambulatory Surgical Centers

        12.5.3. Specialty Clinics

        12.5.4. Others

    12.6. Europe Lyophilized Injectable Market Value  Forecast, by Country/Sub-region, 2018–2032

        12.6.1. Germany

        12.6.2. U.K.

        12.6.3. France

        12.6.4. Spain

        12.6.5. Italy

        12.6.6. Rest of Europe

    12.7. Europe Lyophilized Injectable Market Attractiveness Analysis

        12.7.1. By Type of Packaging

        12.7.2. By Type of Delivery

        12.7.3. By Indication

        12.7.4. By End-user

        12.7.5. By Country/Sub-region

13. Asia Pacific Lyophilized Injectable Market Analysis and Forecast

    13.1. Introduction

    13.2. Asia Pacific Lyophilized Injectable Market Value  Forecast, by Type of Packaging, 2018–2032

        13.2.1. Single-use Vials

        13.2.2. Point-of-care Reconstitution

        13.2.3. Specialty Packaging

    13.3. Asia Pacific Lyophilized Injectable Market Value  Forecast, by Type of Delivery, 2018–2032

        13.3.1. Prefilled Diluent Syringes

        13.3.2. Proprietary Reconstitution Devices

        13.3.3. Single-step Devices

        13.3.4. Multi-step Devices

    13.4. Asia Pacific Lyophilized Injectable Market Value  Forecast, by Indication, 2018–2032

        13.4.1. Autoimmune Diseases

        13.4.2. Metabolic Conditions

        13.4.3. Infectious Diseases

        13.4.4. Others 

    13.5. Asia Pacific Lyophilized Injectable Market Value  Forecast, by End-user, 2018–2032

        13.5.1. Hospitals

        13.5.2. Ambulatory Surgical Centers

        13.5.3. Specialty Clinics

        13.5.4. Others

    13.6. Asia Pacific Lyophilized Injectable Market Value  Forecast, by Country/Sub-region, 2018–2032

        13.6.1. China

        13.6.2. Japan

        13.6.3. India

        13.6.4. Australia & New Zealand

        13.6.5. Rest of Asia Pacific

    13.7. Asia Pacific Lyophilized Injectable Market Attractiveness Analysis

        13.7.1. By Type of Packaging

        13.7.2. By Type of Delivery

        13.7.3. By Indication

        13.7.4. By End-user 

        13.7.5. By Country/Sub-region

14. Latin America Lyophilized Injectable Market Analysis and Forecast

    14.1. Introduction

    14.2. Latin America Lyophilized Injectable Market Value  Forecast, by Type of Packaging, 2018–2032

        14.2.1. Single-use Vials

        14.2.2. Point-of-care Reconstitution

        14.2.3. Specialty Packaging

    14.3. Latin America Lyophilized Injectable Market Value  Forecast, by Type of Delivery, 2018–2032

        14.3.1. Prefilled Diluent Syringes

        14.3.2. Proprietary Reconstitution Devices

        14.3.3. Single-step Devices

        14.3.4. Multi-step Devices

    14.4. Latin America Lyophilized Injectable Market Value  Forecast, by Indication, 2018–2032

        14.4.1. Autoimmune Diseases

        14.4.2. Metabolic Conditions

        14.4.3. Infectious Diseases

        14.4.4. Others 

    14.5. Latin America Lyophilized Injectable Market Value  Forecast, by End-user, 2018–2032

        14.5.1. Hospitals

        14.5.2. Ambulatory Surgical Centers

        14.5.3. Specialty Clinics

        14.5.4. Others

    14.6. Latin America Lyophilized Injectable Market Value  Forecast, by Country/Sub-region, 2018–2032

        14.6.1. Brazil

        14.6.2. Mexico

        14.6.3. Rest of Latin America

    14.7. Latin America Lyophilized Injectable Market Attractiveness Analysis

        14.7.1. By Type of Packaging

        14.7.2. By Type of Delivery

        14.7.3. By Indication

        14.7.4. By End-user 

        14.7.5. By Country/Sub-region

15. Middle East & Africa Lyophilized Injectable Market Analysis and Forecast

    15.1. Introduction

    15.2. Middle East & Africa Lyophilized Injectable Market Value  Forecast, by Type of Packaging, 2018–2032

        15.2.1. Single-use Vials

        15.2.2. Point-of-care Reconstitution

        15.2.3. Specialty Packaging

    15.3. Middle East & Africa Lyophilized Injectable Market Value  Forecast, by Type of Delivery, 2018–2032

        15.3.1. Prefilled Diluent Syringes

        15.3.2. Proprietary Reconstitution Devices

        15.3.3. Single-step Devices

        15.3.4. Multi-step Devices

    15.4. Middle East & Africa Lyophilized Injectable Market Value  Forecast, by Indication, 2018–2032

        15.4.1. Autoimmune Diseases

        15.4.2. Metabolic Conditions

        15.4.3. Infectious Diseases

        15.4.4. Others 

    15.5. Middle East & Africa Lyophilized Injectable Market Value  Forecast, by End-user, 2018–2032

        15.5.1. Hospitals

        15.5.2. Ambulatory Surgical Centers

        15.5.3. Specialty Clinics

        15.5.4. Others

    15.6. Middle East & Africa Lyophilized Injectable Market Value  Forecast, by Country/Sub-region, 2018–2032

        15.6.1. GCC Countries

        15.6.2. South Africa

        15.6.3. Rest of Middle East & Africa

    15.7. Middle East & Africa Lyophilized Injectable Market Attractiveness Analysis

        15.7.1. By Type of Packaging

        15.7.2. By Type of Delivery

        15.7.3. By Indication

        15.7.4. By End-user 

        15.7.5. By Country/Sub-region

16. Competition Landscape

    16.1. Market Position Analysis, by Company, 2019

    16.2. Company Profiles

        16.2.1. B. Braun Melsungen AG

            16.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.1.2. Growth Strategies

            16.2.1.3. SWOT Analysis

        16.2.2. Baxter International, Inc.

            16.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.2.2. Growth Strategies

            16.2.2.3. SWOT Analysis

        16.2.3. BD

            16.2.3.1. Company Overview (HQ, Business Segments)

            16.2.3.2. Growth Strategies

            16.2.3.3. SWOT Analysis

        16.2.4. SCHOTT AG

            16.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.4.2. Growth Strategies

            16.2.4.3. SWOT Analysis

        16.2.5. Aristopharma Ltd.

            16.2.5.1. Company Overview (HQ, Business Segments)

            16.2.5.2. Growth Strategies

            16.2.5.3. SWOT Analysis

        16.2.6. Vetter Pharma

            16.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.6.2. Growth Strategies

            16.2.6.3. SWOT Analysis

        16.2.7. Jubilant HollisterStier LLC

            16.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            16.2.7.2. Growth Strategies

            16.2.7.3. SWOT Analysis

 

Proceed To Buy

USD 4500
USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers